GlassScriptPhysician profile
Ian S Shupack
NPI 1629186481
$9,529.14
in general payments reported to CMS, 2019-2025
55 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,281 · 2020: $1,527 · 2021: $1,478 · 2022: $1,675 · 2023: $1,459 · 2024: $916 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,544 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,543.78 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,176.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,170.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $876.44 | 2019-2025 | |
| Abbvie INC. | $850.03 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $734.95 | 2019-2025 | Mounjaro, Emgality, Zepbound |
| Amgen INC. | $433.31 | 2019-2025 | Otezla, Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.63 | 2019-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $308.74 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $285.94 | 2019-2021 | |
| Glaxosmithkline, LLC. | $283.18 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.40 | 2020-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $215.87 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Teva Pharmaceuticals USA, INC. | $178.13 | 2019-2025 | Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $177.67 | 2022 | |
| Esperion Therapeutics, INC. | $176.95 | 2020-2025 | Nexletol |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Shupack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.